E. Krognes - Jan 5, 2024 Form 4 Insider Report for Denali Therapeutics Inc. (DNLI)

Role
Director
Signature
/s/ Tyler Nielsen, by power of attorney
Stock symbol
DNLI
Transactions as of
Jan 5, 2024
Transactions value $
-$62,331
Form type
4
Date filed
1/9/2024, 07:34 PM
Previous filing
Jan 2, 2024
Next filing
Feb 1, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DNLI Common Stock Sale -$62.3K -3.21K -2.2% $19.43 143K Jan 5, 2024 Direct F1, F2, F3
holding DNLI Common Stock 850K Jan 5, 2024 See footnote F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units.
F2 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $19.37 to $19.43 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3 Includes 24,002 RSUs.
F4 The shares are held of record by The Steve Edward Krognes Revocable Trust U/A DTD 01/25/2016, for which the Reporting Person serves as trustee.